Simplicity Wealth LLC Invests $1.88 Million in Pfizer Inc. (NYSE:PFE)

Simplicity Wealth LLC acquired a new position in Pfizer Inc. (NYSE:PFE - Free Report) during the first quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 74,243 shares of the biopharmaceutical company's stock, valued at approximately $1,881,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Lipe & Dalton grew its position in shares of Pfizer by 17.7% in the 4th quarter. Lipe & Dalton now owns 2,659 shares of the biopharmaceutical company's stock worth $71,000 after buying an additional 400 shares during the last quarter. Beam Wealth Advisors Inc. increased its position in shares of Pfizer by 1.5% in the 4th quarter. Beam Wealth Advisors Inc. now owns 27,444 shares of the biopharmaceutical company's stock valued at $728,000 after acquiring an additional 401 shares during the period. Providence Capital Advisors LLC raised its position in Pfizer by 0.4% during the fourth quarter. Providence Capital Advisors LLC now owns 114,358 shares of the biopharmaceutical company's stock worth $3,034,000 after acquiring an additional 409 shares during the period. Donaldson Capital Management LLC raised its stake in Pfizer by 1.2% in the 4th quarter. Donaldson Capital Management LLC now owns 35,694 shares of the biopharmaceutical company's stock valued at $947,000 after purchasing an additional 410 shares during the last quarter. Finally, Noesis Capital Mangement Corp lifted its position in Pfizer by 2.6% during the fourth quarter. Noesis Capital Mangement Corp now owns 16,357 shares of the biopharmaceutical company's stock worth $434,000 after buying an additional 413 shares in the last quarter. Institutional investors own 68.36% of the company's stock.

Pfizer Stock Up 1.0%

Shares of PFE traded up $0.24 during mid-day trading on Thursday, reaching $24.72. 18,293,593 shares of the stock traded hands, compared to its average volume of 40,987,705. The firm has a market cap of $140.54 billion, a price-to-earnings ratio of 17.53, a P/E/G ratio of 0.64 and a beta of 0.57. The stock has a fifty day simple moving average of $22.96 and a 200 day simple moving average of $24.98. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, topping the consensus estimate of $0.67 by $0.25. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company had revenue of $13.72 billion during the quarter, compared to analyst estimates of $14.43 billion. During the same quarter last year, the firm earned $0.82 EPS. The business's revenue was down 7.8% on a year-over-year basis. Sell-side analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 13th. Stockholders of record on Friday, May 9th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 6.96%. The ex-dividend date is Friday, May 9th. Pfizer's dividend payout ratio (DPR) is presently 124.64%.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the stock. Cantor Fitzgerald started coverage on shares of Pfizer in a research note on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 target price on the stock. Hsbc Global Res raised shares of Pfizer to a "strong-buy" rating in a research report on Monday, March 10th. Citigroup reiterated a "neutral" rating on shares of Pfizer in a research note on Thursday, March 27th. Guggenheim reaffirmed a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. Finally, UBS Group lifted their target price on shares of Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a report on Wednesday, April 30th. One analyst has rated the stock with a sell rating, eight have issued a hold rating, four have assigned a buy rating and three have given a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $29.17.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.